| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. | |
| | |
MedLine Citation:
|
PMID: 21146205 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma. METHODS: Patients (aged 18-65 years) with previously untreated symptomatic myeloma were enrolled from 73 sites in Italy between May, 2006, and April, 2008, and data collection continued until June 30, 2010. Patients were randomly allocated (1:1 ratio) by a web-based system to receive three 21-day cycles of thalidomide (100 mg daily for the first 14 days and 200 mg daily thereafter) plus dexamethasone (40 mg daily on 8 of the first 12 days, but not consecutively; total of 320 mg per cycle), either alone or with bortezomib (1·3 mg/m(2) on days 1, 4, 8, and 11). The randomisation sequence was computer generated by the study coordinating team and was stratified by disease stage. After double autologous stem-cell transplantation, patients received two 35-day cycles of their assigned drug regimen, VTD or TD, as consolidation therapy. The primary endpoint was the rate of complete or near complete response to induction therapy. Analysis was by intention to treat. Patients and treating physicians were not masked to treatment allocation. This study is still underway but is not recruiting participants, and is registered with ClinicalTrials.gov, number NCT01134484, and with EudraCT, number 2005-003723-39. FINDINGS: 480 patients were enrolled and randomly assigned to receive VTD (n=241 patients) or TD (n=239). Six patients withdrew consent before start of treatment, and 236 on VTD and 238 on TD were included in the intention-to-treat analysis. After induction therapy, complete or near complete response was achieved in 73 patients (31%, 95% CI 25·0-36·8) receiving VTD, and 27 (11%, 7·3-15·4) on TD (p<0·0001). Grade 3 or 4 adverse events were recorded in a significantly higher number of patients on VTD (n=132, 56%) than in those on TD (n=79, 33%; p<0·0001), with a higher occurrence of peripheral neuropathy in patients on VTD (n=23, 10%) than in those on TD (n=5, 2%; p=0·0004). Resolution or improvement of severe peripheral neuropathy was recorded in 18 of 23 patients on VTD, and in three of five patients on TD. INTERPRETATION: VTD induction therapy before double autologous stem-cell transplantation significantly improves rate of complete or near complete response, and represents a new standard of care for patients with multiple myeloma who are eligible for transplant. FUNDING: Seràgnoli Institute of Haematology at the University of Bologna, Bologna, Italy. |
| | |
Authors:
|
Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani; |
Related Documents
:
|
21162605 - Topical issues in venous thromboembolism. 16454145 - Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold ... 21335355 - Lesions of the biceps pulley. 21086195 - Risk factors for revision of hip arthroplasties in patients younger than 30 years. 18306145 - Stent-graft applications in peripheral non-atherosclerotic arterial lesions. 10743815 - Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondylo... |
Publication Detail:
|
Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-12-09 |
Journal Detail:
|
Title: Lancet Volume: 376 ISSN: 1474-547X ISO Abbreviation: Lancet Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-20 Completed Date: 2011-01-03 Revised Date: 2011-12-07 |
Medline Journal Info:
|
Nlm Unique ID: 2985213R Medline TA: Lancet Country: England |
Other Details:
|
Languages: eng Pagination: 2075-85 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy. michele.cavo@unibo.it |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT01134484 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Boronic Acids / administration & dosage, adverse effects Chemotherapy, Adjuvant Dexamethasone / administration & dosage, adverse effects Disease-Free Survival Drug Administration Schedule Female Hematopoietic Stem Cell Transplantation* Humans Italy Kaplan-Meier Estimate Male Middle Aged Multiple Myeloma / diagnosis, drug therapy*, surgery* Neoadjuvant Therapy / methods* Pyrazines / administration & dosage, adverse effects Remission Induction Reoperation Thalidomide / administration & dosage, adverse effects Transplantation, Autologous Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Boronic Acids; 0/Pyrazines; 0/bortezomib; 50-02-2/Dexamethasone; 50-35-1/Thalidomide |
| Investigator | |
Investigator/Affiliation:
|
G Perrone / ; A Brioli / ; A Petrucci / ; M R Motta / ; S Rizzi / ; R Fanin / ; S Buttignol / ; R Foà / ; E Calabrese / ; A Rambaldi / ; G Rossi / ; S Ferrari / ; M Boccadoro / ; S Bringhen / ; P Leoni / ; C Polloni / ; V Montefusco / ; G Torelli / ; G Fioritoni / ; S Cortelazzo / ; A Billio / ; L Baldini / ; F Onida / ; C Annaloro / ; G La Nasa / ; A Zaccaria / ; P De Fabritiis / ; A Siniscalchi / ; N Cascavilla / ; A Falcone / ; A Bosi / ; C Nozzoli / ; G Semenzato / ; R Zambello / ; L Gugliotta / ; L Masini / ; F Gherlinzoni / ; A Furlan / ; E Angelucci / ; D Derudas / ; M Martelli / ; S Ballanti / ; M C Petti / ; F Pisani / ; G Leone / ; V De Stefano / ; A M Carella / ; G Catania / ; F Ciceri / ; J Peccatori / ; A Santoro / ; L Castagna / ; F Ferrara / ; S Palmieri / ; F Nobile / ; V Callea / ; A M D'Arco / ; C Califano / ; A Levis / ; A Baraldi / ; L Guardigni / ; S Pasini / ; A Gallamini / ; M Grasso / ; P Musto / ; M Barone / ; P Fattori / ; E Pasquini / ; P Galieni / ; M Ruggieri / ; S Morandi / ; M Tajana / ; D Amadori / ; S Ronconi / ; D Cangini / ; M Gobbi / ; F Ballerini / ; L Catalano / ; C Cangialosi / ; A Lazzaro / ; G Paladini / ; G De Sabbata / ; R Mozzana / ; F Ciambelli / ; G Pinotti / ; F Rodeghiero / ; F Elice / ; N Cantore / ; S Volpe / ; V Pavone / ; A Mele / ; E Pogliani / ; F Rossini / ; A M Liberati / ; I Majolino / ; L De Rosa / ; S Amadori / ; M Rizzo / ; F Lauria / ; A Gozzetti / ; M Aglietta / ; A Capaldi / ; G Quarta / ; G Mele / ; S Storti / ; V Fraticelli / ; F Morabito / ; C Gentile / ; S Capalbo / ; A M Gianni / ; M Magni / ; V Mettivier / ; G R Nunziata / ; V Rizzoli / ; M Crugnola / ; C Bernasconi / ; V Fregoni / ; G Visani / ; A Olivieri / ; M Pizzuti / ; G La Verde / ; A Moscetti / ; G Avvisati / ; M C Tirindelli / ; M Longinotti / ; L Podda / ; E Gallo / ; P Pregno / ; F Dammacco / ; F Perosa / ; D Russo / ; A Roccaro / ; A Bacigalupo / ; A Dominietto / ; C Musolino / ; E Quartarone / |
| Comments/Corrections | |
Comment In:
|
Lancet. 2010 Dec 18;376(9758):2043-4
[PMID:
21146204
]
|
Erratum In:
|
Lancet. 2011 Nov 26;378(9806):1846 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gun carrying by high school students in Boston, MA: Does overestimation of peer gun carrying matter?
Next Document: Burden of endemic health-care-associated infection in developing countries: systematic review and me...